IL2 and COVID-19: The administration of low‐dose recombinant IL‐2 in COVID‐19 patients has been proposed as an alternative therapeutic strategy to control ARDS and excessive inflammation by expanding and activating Tregs; a clinical trial has been registered (NCT04357444) (Figure 2C, Table 1).